## **REMARKS**

The present amendment adds an Abstract of the Disclosure on a separate sheet and modifies the claim format only so as to eliminate the use of multiple dependency.

An Information Disclosure Statement is filed concurrently herewith.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Bv

Benton S. Duffett, Jr. Registration No. 22,030

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: December 31, 2001

## Attachment to Amendment dated December 31, 2001

## Marked-up Claims 11, 17, 19, and 22

- 11. (Amended) Adenovirus according to [any of the claims 1 10] <u>claim 1</u>, characterized in that the new cellbinding ligand is any cellbinding peptide.
- 17. (Amended) Adenovirus according to [any of the preceding claims] <u>claim 1</u>, characterized in that an external nuclear localisation signal (NLS) has been introduced in the fiber.
- 19. (Amended) Adenovirus according to [any of the preceding claims] claim 1, characterized in that the fiber in addition contains sequences which increase the survival of the fiber in the cytosol of infected cells, thereby enhancing transportation into the nucleus and virus assembly.
- 22. (Amended) Adenovirus according to [claims 1 21] <u>claim 1</u> for the treatment of human diseases, either in vivo or by in vitro methods.

10/019566 531 Rec'd PCT/T 31 DEC 2001

Application No. (unassigned)
Attorney's Docket No. 003300-883
Page 1

# Attachment to Amendment dated December 31, 2001

#### **Abstract of the Disclosure**

Recombinant adenovirus with changed tropism is provided. In the adenovirus the native pentone fibre, comprising a fibre tail, a fibre shaft and a fibre knob including a trimerisation motif, has been changed in that the native knob containing the cell binding structure and the native trimerisation motif has been removed and a new cellbinding ligand and an external trimerisation motif have been introduced into the virus fiber. Further, the invention relates to the recombinant adenovirus for the treatment of human diseases, either in vivo or by in vitro methods and also to a method for rescuing of recombinant adenovirus fibers into the adenovirus genome.